Genmab A/S (GMAB) News Today

Genmab A/S (NASDAQ:GMAB) shares are trading higher today after the stock hit a new 1‑year high and analysts continue to show overall conviction, but the move is being balanced by fresh downward FY2026 estimate revisions and a notable rise in short interest. Below are the key items investors should know and how they may influence the share price.

• Positive Sentiment: Stock set a new 1‑year high, signaling strong buying momentum and technical interest that can attract momentum traders. Genmab A/S (NASDAQ:GMAB) Hits New 1-Year High - What's Next?
• Positive Sentiment: HC Wainwright continues to carry a Buy rating with a $40 target and issued upgrades to some near-term 2025 estimates (supporting sentiment that near‑term fundamentals look stronger). What is HC Wainwright's Estimate for Genmab A/S Q3 Earnings?
• Neutral Sentiment: Consensus from brokers is a "Moderate Buy" (11 analysts), which supports demand but leaves room for differing views and volatility around guidance and pipeline news. Genmab Receives Average Recommendation of "Moderate Buy"
• Negative Sentiment: HC Wainwright cut Q2–Q4 and FY2026 EPS forecasts (reducing FY2026 from $2.38 to $2.26), which introduces earnings risk for 2026 and could cap upside until guidance clarity arrives. HC Wainwright Has Negative Outlook of Genmab A/S Q2 Earnings
• Negative Sentiment: Leerink/others trimmed FY2026 EPS estimates, signaling some analyst concern about next‑year growth and potentially pressuring multiple expansion. FY2026 EPS Estimates for Genmab A/S Cut by Leerink Partners
• Negative Sentiment: Short interest jumped ~59% in September to ~5.56M shares (≈0.9% of float), raising the potential for near‑term volatility — both downside pressure from short selling and squeeze risk if positive catalysts continue.